Community Research and Development Information Service - CORDIS

Periodic Report Summary 1 - CD300SHIV (The CD300 family of receptors in HIV infection)

Significant advances in antiretroviral therapy have allowed the control of the viremia in most patients infected with HIV, which has led to a large reduction in mortality associated with this disease. However, it is not clear yet all the causes of chronic activation as well as the mechanisms leading to immunosuppression and exhaustion, and why the Immune System is not able of controlling the virus in most infected individuals.
The human CD300 (CD300a-h) molecules are capable of recognizing phospholipids, such as phosphatidylserine (PS) and phosphatidylethanolamine (PE), which are exposed on the outer leaflet of the plasma membrane of dead and activated cells. PS and PE are to the inner sheet of the plasma membrane of live and resting cells. Loss of plasma membrane asymmetry, with exposure of PS and PE on the outer leaflet, occurs during apoptosis, cell injury, cell activation, malignant transformation and viral infection. To efficiently replicate, viruses such as human immunodeficiency virus (HIV), activate the host cells leading to an increase in the intracellular calcium, which in turn causes externalization of PS and PE. Moreover, translocation of these two phospholipids to the outer leaflet of the plasma membrane is one of the earliest events associated with apoptosis induced by viruses, such as HIV.
Our hypothesis predicts that inhibitory and activating receptors of the CD300 family of molecules have a role in the chronic immune activation and in the T cell exhaustion that are observed in patients chronically infected by HIV, and in the mechanisms that the virus use to evade the attack by cytotoxic lymphocytes, namely CD8+ T cells and natural killer (NK) cells. Therefore, the project's main objective is to study the role of the CD300 receptor family in the pathogenesis of the infection by HIV and viral escape mechanisms.
During the first two years of this project we have made important advances in our knowledge about the expression and function of human CD300 receptors, in the establishment of our group (Immunopathology Group http://biocruces.com/web/biocruces/bc4.09) and in initiating collaborations to obtain patient´s samples:
1.-: Our group was created in March 2013 only with funding for the PI salary. Until today the PI has gotten several funded projects and currently the team is composed of a postdoctoral researcher and a predoctoral fellow. The latter was very briefly funded with this Career Integration Grant until she got a fellowship from the Basque Government.
2.-: We are using blood samples collected from HIV-infected patients as well as from healthy donors. Samples are collected through the Basque Biobank and National Biobank for HIV under an institutional review board-approved protocol by the Basque Committee of Ethics and Clinical Research. All study subjects provided written informed consent. We have also obtained samples from our collaborators from the Virgen del Rocío Hospital in Seville, Spain.
3.-: A fundamental part of our efforts have been dedicated to disseminating our results. During this period we have published a review article about the biology and disease relevance of the CD300a inhibitory receptor and an original article describing the differences in the expression and function of the CD300 family of receptors in mononuclear cells from neonates and adults. In addition, we are also preparing a manuscript with the findings we have obtained from a cohort of HIV-infected patients that have received a modified vaccinia Ankara-based HIV-1 vaccine and its relationship to CD300 molecules expression on circulating monocytes.

Contact

Idoia Mínguez, (R+D+i International Projects Manager)
Tel.: +34944536885
Fax: +34944530465
E-mail

Subjects

Life Sciences
Record Number: 192297 / Last updated on: 2016-12-15
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top